Hansoh Pharma presents phase 2b data: what it means for Hansoh Pharma stock

Published on 10/13/2026 at 03:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The study randomized 363 patients and supports a phase 3 move. For Hansoh Pharma stock, this adds 19.30 percent weight loss from phase III data.

Hansoh Pharma presented phase 2b schizophrenia data from a 363-participant study on October 12, 2026.
The study supports moving HS-10380 into phase 3 after PANSS improvements versus placebo at Day 42.
Olatorepatide produced 19.30 percent mean weight loss at Week 48 in a separate phase III study.
Hansoh Pharma was last at EUR 3.60 at Lang & Schwarz on October 12, 2026, while its HKD 28.06 to HKD 44.22 52-week range frames the Hong Kong listing.

Hansoh Pharma, KYG549581067, Illustration mit AI erstellt.

Hansoh Pharma (KYG549581067) presented phase 2b schizophrenia data from a 363-participant study on October 12, 2026. According to Hansoh Pharma, the results support moving HS-10380 into phase 3, giving the pipeline a concrete clinical milestone.

What does phase 2b mean?

The randomized study assigned 363 adults with acute schizophrenia to three HS-10380 dose groups, aripiprazole or placebo. At Day 42, the least-squares mean PANSS total-score difference versus placebo was -16.70 for the 1.5 to 3 mg group, -13.20 for the 4.5 to 6 mg group and -14.70 for the 6 to 9 mg group, while aripiprazole recorded -12.10.

The company described the safety profile as favorable, with most treatment-emergent adverse events mild to moderate and no new significant safety concerns. The evidence is still from phase 2b, so the planned phase 3 step is the next development test rather than a commercial approval.

Three pipeline milestones in 2026

On September 13, 2026, Hansoh reported phase 3 ARTEMIS-008 results in 461 patients, including median overall survival of 18.50 months versus 10.30 months for topotecan. The company linked those results to a 54.00 percent reduction in the risk of death in its release.

On September 21, 2026, HS-10374 met co-primary endpoints in a phase 3 plaque-psoriasis trial. MarketScreener reported on the September 21, 2026 release that both PASI 75 and sPGA 0/1 response rates were higher than placebo at Week 16.

On October 2, 2026, Hansoh reported phase III LIGHTEN data for olatorepatide in 604 participants. According to Hansoh Pharma, mean weight loss at Week 48 reached 19.30 percent in the 15 mg group versus 2.70 percent with placebo, a 16.60 percentage-point difference.

Pipeline breadth meets market scale

Hansoh Pharma's latest disclosures combine central nervous system, oncology, autoimmune and metabolic programs. The company's financial-information page lists its interim report for the six months ended June 30, 2026, dated September 23, 2026, while the official website identifies Hong Kong listing code 03692.HK and seven innovative drugs generating sales in China.

Market data put Hansoh Pharma's market capitalization at HKD 191.3 billion and its 52-week range at HKD 28.06 to HKD 44.22 as of October 13, 2026. The range places the latest HKEX quote inside a broad valuation band, while the clinical releases supply the operating events behind the stock's pipeline narrative.

Last euro quote and trading frame

The last Lang & Schwarz quote was EUR 3.60 on October 12, 2026 at 10:57 p.m. CEST. The primary listing is on the Hong Kong Stock Exchange, where Hansoh Pharma trades under 3692.HK; the Hong Kong market data timestamp was October 13, 2026 at 9:25 a.m. HKT.

The further course of trading is shown by the continuously updated real-time quote of Hansoh Pharma stock.